The long and short of antibiotic management for neutropenic fever in patients with haematological malignancy

Affiliations

¹ Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia. Electronic address: ben.teh@petermac.org.

Comment

Benjamin W Teh. Lancet Haematol. 2022 Aug.

. 2022 Aug;9(8):e548-e549.

doi: 10.1016/S2352-3026(22)00179-X. Epub 2022 Jun 9.

¹ Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia. Electronic address: ben.teh@petermac.org.

No abstract available

Conflict of interest statement

BWT is on the advisory board for CSL-Behring and Takeda and has received research funding from Merck Sharp and Dohme, Sanofi, and Seqirus.

Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial.
de Jonge NA, Sikkens JJ, Zweegman S, Beeker A, Ypma P, Herbers AH, Vasmel W, de Kreuk A, Coenen JLLM, Lissenberg-Witte B, Kramer MHH, van Agtmael MA, Janssen JJWM. de Jonge NA, et al. Lancet Haematol. 2022 Aug;9(8):e563-e572. doi: 10.1016/S2352-3026(22)00145-4. Epub 2022 Jun 9. Lancet Haematol. 2022. PMID: 35691326 Clinical Trial.